Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer

BACKGROUND: This dose-finding study evaluated lenvatinib, an oral multitargeted receptor tyrosine kinase inhibitor, in combination with carboplatin/paclitaxel in chemotherapy-naïve non-small-cell lung cancer (NSCLC) patients. PATIENTS AND METHODS: Patients received lenvatinib twice daily (BID) with...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishio, M, Horai, T, Horiike, A, Nokihara, H, Yamamoto, N, Takahashi, T, Murakami, H, Koizumi, F, Nishio, K, Yusa, W, Koyama, N, Tamura, T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3738144/
https://www.ncbi.nlm.nih.gov/pubmed/23860537
http://dx.doi.org/10.1038/bjc.2013.374

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3738144/
https://www.ncbi.nlm.nih.gov/pubmed/23860537
http://dx.doi.org/10.1038/bjc.2013.374

Ejemplares similares